← All trials
NCT05553405
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Jan 1, 2033
- Completion date
- Jan 1, 2033
- First posted
- Sep 23, 2022
- Last posted
- Oct 10, 2022
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityOverall official - principal investigator
- Yale UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.